These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19806501)

  • 21. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer.
    Shmulevitz M; Marcato P; Lee PW
    Oncogene; 2005 Nov; 24(52):7720-8. PubMed ID: 16299532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy.
    Twigger K; Vidal L; White CL; De Bono JS; Bhide S; Coffey M; Thompson B; Vile RG; Heinemann L; Pandha HS; Errington F; Melcher AA; Harrington KJ
    Clin Cancer Res; 2008 Feb; 14(3):912-23. PubMed ID: 18245555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncolytic viral therapies - the clinical experience.
    Aghi M; Martuza RL
    Oncogene; 2005 Nov; 24(52):7802-16. PubMed ID: 16299539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modification of mammalian reoviruses for use as oncolytic agents.
    Van Den Wollenberg DJ; Van Den Hengel SK; Dautzenberg IJ; Kranenburg O; Hoeben RC
    Expert Opin Biol Ther; 2009 Dec; 9(12):1509-20. PubMed ID: 19916732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.
    White CL; Twigger KR; Vidal L; De Bono JS; Coffey M; Heinemann L; Morgan R; Merrick A; Errington F; Vile RG; Melcher AA; Pandha HS; Harrington KJ
    Gene Ther; 2008 Jun; 15(12):911-20. PubMed ID: 18323793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic parvoviruses as cancer therapeutics.
    Rommelaere J; Geletneky K; Angelova AL; Daeffler L; Dinsart C; Kiprianova I; Schlehofer JR; Raykov Z
    Cytokine Growth Factor Rev; 2010; 21(2-3):185-95. PubMed ID: 20211577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trials involving the oncolytic virus, reovirus: ready for prime time?
    Black AJ; Morris DG
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):517-20. PubMed ID: 23121273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
    Rodríguez Stewart RM; Berry JTL; Berger AK; Yoon SB; Hirsch AL; Guberman JA; Patel NB; Tharp GK; Bosinger SE; Mainou BA
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reovirus: a targeted therapeutic--progress and potential.
    Maitra R; Ghalib MH; Goel S
    Mol Cancer Res; 2012 Dec; 10(12):1514-25. PubMed ID: 23038811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma.
    Pandha HS; Heinemann L; Simpson GR; Melcher A; Prestwich R; Errington F; Coffey M; Harrington KJ; Morgan R
    Clin Cancer Res; 2009 Oct; 15(19):6158-66. PubMed ID: 19773377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.
    Harrington KJ; Vile RG; Melcher A; Chester J; Pandha HS
    Cytokine Growth Factor Rev; 2010; 21(2-3):91-8. PubMed ID: 20223697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Not all viruses are bad guys: the case for reovirus in cancer therapy.
    Norman KL; Lee PW
    Drug Discov Today; 2005 Jun; 10(12):847-55. PubMed ID: 15970267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
    Rajani K; Parrish C; Kottke T; Thompson J; Zaidi S; Ilett L; Shim KG; Diaz RM; Pandha H; Harrington K; Coffey M; Melcher A; Vile R
    Mol Ther; 2016 Feb; 24(1):166-74. PubMed ID: 26310630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus.
    Zhao X; Chester C; Rajasekaran N; He Z; Kohrt HE
    Mol Cancer Ther; 2016 May; 15(5):767-73. PubMed ID: 27197256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppression promotes reovirus therapy of colorectal liver metastases.
    Smakman N; van der Bilt JD; van den Wollenberg DJ; Hoeben RC; Borel Rinkes IH; Kranenburg O
    Cancer Gene Ther; 2006 Aug; 13(8):815-8. PubMed ID: 16543920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.
    Mohamed A; Johnston RN; Shmulevitz M
    Viruses; 2015 Dec; 7(12):6251-78. PubMed ID: 26633466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noncanonical Cell Death Induction by Reassortant Reovirus.
    Rodríguez Stewart RM; Raghuram V; Berry JTL; Joshi GN; Mainou BA
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.
    Qiao J; Wang H; Kottke T; White C; Twigger K; Diaz RM; Thompson J; Selby P; de Bono J; Melcher A; Pandha H; Coffey M; Vile R; Harrington K
    Clin Cancer Res; 2008 Jan; 14(1):259-69. PubMed ID: 18172278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncolytic vaccinia virus: from bedside to benchtop and back.
    Thorne SH
    Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.